Theralase Closes Equity Financing
Friday, 13 April 2012 12:53 PM
Toronto, Ontario - April 13, 2012 Theralase Technologies Inc. (TSX-V: TLT) is pleased to announce that it has closed a previously announced private placement (the "Private Placement") of 3,000,000 units (the "Units") at a price of Cdn $0.25 per Unit for gross proceeds of CDN $750,000.00. Each Unit consists of one common share in the capital of the Company and one-half of one non-transferable common share purchase warrant (a "Warrant"). Each whole Warrant entitles the purchaser to purchase one additional common share (a "Warrant Share") in the capital of the Company until April 13, 2013 at a price of CDN $0.38 per Warrant Share. The securities issued under the Private Placement including any shares issued upon exercise of the Warrants are subject to a four month hold period, expiring August 13, 2012.
The company intends to utilize the proceeds of the offering to provide additional working capital to further develop the Company's prospects in a number of areas; specifically:
-USA sales and marketing expansion
-Small animal cancer trials at the Ontario Cancer Institute, Princess Margaret Hospital, University Health Network
-Research and development of Photo Dynamic Compounds (PDCs) for the destruction of bacteria and viruses
-Next generation TLC-2000 therapeutic medical biofeedback laser commercialization
About Theralase Technologies Inc.:
Theralase Technologies Inc., founded in 1995, designs, develops, manufactures and markets patented, superpulsed laser technology utilized in biostimulation and biodestruction applications. Theralase technology is safe and effective in treating pain, inflammation and for tissue regeneration of neural muscular skeletal conditions and wound healing. Theralase is currently developing patented Photo Dynamic Compounds (PDCs) that are able to target and destroy cancers, bacteria and viruses when light activated by Theralase's proprietary and patented laser technology.
For further information please visit www.theralase.com, regulatory filings may be viewed by visiting www.sedar.com.
This press release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.
For More Information:
Roger Dumoulin-White
President & CEO,
416-447-8455 ext. 225
Kristina Hachey
CFO
416-447-8455 ext. 224
Greg Bewsh
Director of Investor Relations,
416-447-8455 ext. 262
